Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic

Vyriad announces an expansion of a Phase 1 investigator-initiated trial at Mayo Clinic evaluating the safety and efficacy of Voyager-V1 (VSV-hIFNbeta-NIS) in patients with peripheral T-cell lymphoma (PTCL) following encouraging initial results. Voyager-V1 is an investigational therapy being co-developed with Regeneron Pharmaceuticals, Inc., to treat patients with recurrent or treatment-resistant cancers. It is an oncolytic virotherapy designed to target and dissolve cancer cells and stimulate the patient’s immune system in hopes of preventing recurrence.

“The expansion of this Phase 1 program is an important step toward delivering targeted genetic medicines to patients with resistant peripheral T-cell lymphoma,” said Stephen Russell, MD, Vyriad chief executive officer and chief scientific officer. “Early Phase 1 results offered an indication that a single infusion of Voyager-V1 has the potential to provide significant benefit to patients with PTCL, a cancer with a generally poor prognosis.”

PTCLs comprise a diverse group of uncommon and aggressive diseases in which the patient’s T cells become cancerous. PTCLs are a varied group of diseases that are not well understood. Techniques to distinguish and study the various subtypes of PTCL have only recently been developed.  Current first-line therapies for patients with PTCL can be curative, but most patients will experience a recurrence of the disease.

Funding for the trial is provided by Regeneron, the National Institutes of Health, and Vyriad. The trial is being conducted at Mayo Clinic Rochester and Mayo Clinic Arizona.